Novo Nordisk Stock - Analyst consensus and GLP-1 momentum
20.06.2026 - 20:32:35 | ad-hoc-news.de
Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 18:20 UTC. Details in the imprint.
Novo Nordisk (DK0062498333) remains one of the most closely watched healthcare names globally via its New York-listed ADR NVO. With no fresh corporate headlines this weekend, the focus shifts to analyst consensus and the long-term GLP-1 franchise driving the stock.
All news and data on Novo Nordisk stock
Key figures, filings and previous headlines give additional context for how Novo Nordisk’s GLP-1 business shapes the NVO ADR over time.
What analysts currently say
Analyst services describe Novo Nordisk’s ADR as trading near the mid-40s in USD, with Arincen showing NVO around $43.19 at the last close, implying a market capitalization above $190 billion. Zacks recently highlighted a roughly 21% one-month rally in NVO earlier this year.
Zacks assigns the stock a Rank #3 (Hold), citing robust GLP-1 demand but also pricing pressure, intensifying competition from Eli Lilly and regulatory uncertainties. Other data aggregators such as TradingKey summarize the current rating as “hold” with an average price target near $49.61.
Consensus, valuation and growth drivers
At roughly $43 per ADR and a trailing price-to-earnings ratio around 10 on Arincen’s figures, Novo Nordisk trades at a notable discount to many high-growth US healthcare peers, despite double-digit sales growth in key GLP-1 therapies.
Net-net, consensus still expects continued revenue expansion driven by obesity and diabetes treatments, while flagging capacity constraints, reimbursement policy changes and future competition as the main risks around the current valuation.
How the company makes money
Novo Nordisk generates the majority of its revenue from diabetes and obesity care, led by GLP-1 products such as Ozempic for type 2 diabetes and Wegovy for chronic weight management, alongside a broad portfolio of insulin and rare-disease therapies.
Where the stock trades today
The shares of Novo Nordisk ADR (DK0062498333) trade on the New York Stock Exchange under the ticker NVO at $43.19 as of 06/18/2026, 16:00 ET.
Novo Nordisk at a glance
- Company: Novo Nordisk A/S
- ISIN: DK0062498333
- WKN: A3EU6F
- Ticker: NVO
- Venue: NYSE
- Price (as of 06/18/2026, 16:00 ET): 43.19 USD
- Market cap: 191,242,319,159 USD (as of 06/18/2026)
- Sector / Industry: Healthcare / Pharmaceuticals
- Index membership: OMX Copenhagen 25, Stoxx Europe 50, Stoxx Europe 600
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
